Trials / Not Yet Recruiting
Not Yet RecruitingNCT06453239
Assessment the Diagnostic Value of Pro-Neurotensin as a Serum Biomarker in MASLD
Assessment the Diagnostic Value of Pro-Neurotensin as a Serum Biomarker in Metabolic Dysfunction-associated Steatotic Liver Disease
- Status
- Not Yet Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 80 (estimated)
- Sponsor
- Sohag University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Accepted
Summary
To assess the diagnostic significance of serum pro-NT in MASLD and ability to differentiate between early and advanced steatosis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | Pro-Neurotensin level as a Serum Biomarker | Pro-Neurotensin mediates the development of fatty liver disease. Neurotensin (NT) is a 13-amino acid peptide secreted by the neuroendocrine cells of the small intestine in response to fat ingestion, which facilitates fatty acid absorption through the gut in relation to food lipid content. |
Timeline
- Start date
- 2024-07-01
- Primary completion
- 2025-07-01
- Completion
- 2025-08-01
- First posted
- 2024-06-11
- Last updated
- 2024-06-11
Source: ClinicalTrials.gov record NCT06453239. Inclusion in this directory is not an endorsement.